Literature DB >> 30213875

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

Anna Chorzalska1, John Morgan2, Nagib Ahsan3,4, Diana O Treaba5, Adam J Olszewski6, Max Petersen1, Nathan Kingston1, Yan Cheng6, Kara Lombardo5, Christoph Schorl7, Xiaoqing Yu8, Roberta Zini9, Annalisa Pacilli10,11, Alexander Tepper1, Jillian Coburn3, Anita Hryniewicz-Jankowska12,13, Ting C Zhao14, Elena Oancea15, John L Reagan6, Olin Liang6, Leszek Kotula13, Peter J Quesenberry6, Philip A Gruppuso16, Rossella Manfredini9, Alessandro Maria Vannucchi10,11, Patrycja M Dubielecka1.   

Abstract

Although the pathogenesis of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs) is linked to constitutive activation of the JAK-STAT pathway, JAK inhibitors have neither curative nor MPN-stem cell-eradicating potential, indicating that other targetable mechanisms are contributing to the pathophysiology of MPNs. We previously demonstrated that Abelson interactor 1 (Abi-1), a negative regulator of Abelson kinase 1, functions as a tumor suppressor. Here we present data showing that bone marrow-specific deletion of Abi1 in a novel mouse model leads to development of an MPN-like phenotype resembling human PMF. Abi1 loss resulted in a significant increase in the activity of the Src family kinases (SFKs), STAT3, and NF-κB signaling. We also observed impairment of hematopoietic stem cell self-renewal and fitness, as evidenced in noncompetitive and competitive bone marrow transplant experiments. CD34+ hematopoietic progenitors and granulocytes from patients with PMF showed decreased levels of ABI1 transcript as well as increased activity of SFKs, STAT3, and NF-κB. In aggregate, our data link the loss of Abi-1 function to hyperactive SFKs/STAT3/NF-κB signaling and suggest that this signaling axis may represent a regulatory module involved in the molecular pathophysiology of PMF.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30213875      PMCID: PMC6236464          DOI: 10.1182/blood-2018-05-848408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

2.  Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2014-09       Impact factor: 10.047

3.  EPS8 and E3B1 transduce signals from Ras to Rac.

Authors:  G Scita; J Nordstrom; R Carbone; P Tenca; G Giardina; S Gutkind; M Bjarnegård; C Betsholtz; P P Di Fiore
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

Review 4.  Therapy for myeloproliferative neoplasms: when, which agent, and how?

Authors:  Holly L Geyer; Ruben A Mesa
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

5.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.

Authors:  Hajime Akada; Dongqing Yan; Haiying Zou; Steven Fiering; Robert E Hutchison; M Golam Mohi
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

6.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Authors:  Maria Kleppe; Minsuk Kwak; Priya Koppikar; Markus Riester; Matthew Keller; Lennart Bastian; Todd Hricik; Neha Bhagwat; Anna Sophia McKenney; Efthymia Papalexi; Omar Abdel-Wahab; Raajit Rampal; Sachie Marubayashi; Jonathan J Chen; Vincent Romanet; Jordan S Fridman; Jacqueline Bromberg; Julie Teruya-Feldstein; Masato Murakami; Thomas Radimerski; Franziska Michor; Rong Fan; Ross L Levine
Journal:  Cancer Discov       Date:  2015-01-08       Impact factor: 39.397

7.  Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.

Authors:  Ilyas Chachoua; Christian Pecquet; Mira El-Khoury; Harini Nivarthi; Roxana-Irina Albu; Caroline Marty; Vitalina Gryshkova; Jean-Philippe Defour; Gaëlle Vertenoeil; Anna Ngo; Ann Koay; Hana Raslova; Pierre J Courtoy; Meng Ling Choong; Isabelle Plo; William Vainchenker; Robert Kralovics; Stefan N Constantinescu
Journal:  Blood       Date:  2015-12-14       Impact factor: 22.113

8.  Abi1 is essential for the formation and activation of a WAVE2 signalling complex.

Authors:  Metello Innocenti; Adriana Zucconi; Andrea Disanza; Emanuela Frittoli; Liliana B Areces; Anika Steffen; Theresia E B Stradal; Pier Paolo Di Fiore; Marie-France Carlier; Giorgio Scita
Journal:  Nat Cell Biol       Date:  2004-03-28       Impact factor: 28.824

9.  Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation.

Authors:  Patrizia Sini; Angela Cannas; Anthony J Koleske; Pier Paolo Di Fiore; Giorgio Scita
Journal:  Nat Cell Biol       Date:  2004-02-22       Impact factor: 28.824

10.  CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Authors:  Roberta Zini; Paola Guglielmelli; Daniela Pietra; Elisa Rumi; Chiara Rossi; Sebastiano Rontauroli; Elena Genovese; Tiziana Fanelli; Laura Calabresi; Elisa Bianchi; Simona Salati; Mario Cazzola; Enrico Tagliafico; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Blood Cancer J       Date:  2017-12-08       Impact factor: 11.037

View more
  9 in total

1.  TGFBI secreted by tumor-associated macrophages promotes glioblastoma stem cell-driven tumor growth via integrin αvβ5-Src-Stat3 signaling.

Authors:  Peng Peng; Hongtao Zhu; Dan Liu; Zirong Chen; Xiaolin Zhang; Zhongyin Guo; Minhai Dong; Lijun Wan; Po Zhang; Guohao Liu; Suojun Zhang; Fangyong Dong; Feng Hu; Fangling Cheng; Shijun Huang; Dongsheng Guo; Bin Zhang; Xingjiang Yu; Feng Wan
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

2.  miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.

Authors:  F Ferrer-Marín; A B Arroyo; B Bellosillo; E J Cuenca; L Zamora; J M Hernández-Rivas; J C Hernández-Boluda; C Fernandez-Rodriguez; E Luño; C García Hernandez; A Kerguelen; D V Fiallo-Suárez; M T Gómez-Casares; R Ayala; P Vélez; C Boqué; V García-Gutierrez; B Arrizabalaga; N Estrada; R Cifuentes; I Arcas; A M de Los Reyes-García; C Besses; V Vicente; A Alvarez-Larrán; R Teruel-Montoya; R González-Conejero; C Martínez
Journal:  Leukemia       Date:  2020-02-27       Impact factor: 11.528

3.  ABI1-based expression signature predicts breast cancer metastasis and survival.

Authors:  Angelina Regua; Csaba Papp; Andre Grageda; Baylee A Porter; Tiffany Caza; Isabelle Bichindaritz; Mira Krendel; Abirami Sivapiragasam; Gennady Bratslavsky; Vladimir A Kuznetsov; Leszek Kotula
Journal:  Mol Oncol       Date:  2022-01-26       Impact factor: 7.449

4.  Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy.

Authors:  Mayumi Takahashi; Haitang Li; Jiehua Zhou; Pritsana Chomchan; Veenu Aishwarya; Masad J Damha; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-11       Impact factor: 8.886

5.  Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.

Authors:  Nicolas Pelisch; Jose Rosas Almanza; Kyle E Stehlik; Brandy V Aperi; Antje Kroner
Journal:  eNeuro       Date:  2021-03-11

6.  Abi1 mediates airway smooth muscle cell proliferation and airway remodeling via Jak2/STAT3 signaling.

Authors:  Ruping Wang; Yinna Wang; Guoning Liao; Bohao Chen; Reynold A Panettieri; Raymond B Penn; Dale D Tang
Journal:  iScience       Date:  2022-01-29

Review 7.  Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin.

Authors:  Lei Qin; Nian Liu; Chao-le-Meng Bao; Da-Zhi Yang; Gui-Xing Ma; Wei-Hong Yi; Guo-Zhi Xiao; Hui-Ling Cao
Journal:  Acta Pharmacol Sin       Date:  2022-07-27       Impact factor: 7.169

8.  CRISPR/CAS9-mediated knockout of Abi1 inhibits p185Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways.

Authors:  James Faulkner; Peixin Jiang; Delaney Farris; Ryan Walker; Zonghan Dai
Journal:  J Hematol Oncol       Date:  2020-04-10       Impact factor: 23.168

9.  KCTD15 deregulation is associated with alterations of the NF-κB signaling in both pathological and physiological model systems.

Authors:  Giovanni Smaldone; Luigi Coppola; Katia Pane; Monica Franzese; Giuliana Beneduce; Rosanna Parasole; Giuseppe Menna; Luigi Vitagliano; Marco Salvatore; Peppino Mirabelli
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.